Riya Khetan

Dr Riya Khetan

Research Assistant

School of Pharmacy and Biomedical Sciences

College of Health

Eligible to supervise Masters and PhD (as Co-Supervisor) - email supervisor to discuss availability.


Year Citation
2026 Hussain, M. S., Khetan, R., Albrecht, H., Krasowska, M., & Blencowe, A. (2026). Correlation of Polymer–drug Composition with Micelle Properties, Performance, and Cytotoxicity for the Oligoelectrolyte-mediated pH-triggered Release of Hydrophobic Drugs. Polymers, 18(2), 247.
DOI Scopus1 WoS1 Europe PMC1
2026 Khetan, R., Rajapaksha, W., Nturubika, B. D., Gillam, T. A., Brooks, D. A., Garg, S., . . . Eldi, P. (2026). Targeting F2R/PAR1 with ligand decorated lipid nanocarriers for enhanced drug delivery into ovarian cancer cells.. Front Drug Deliv, 5, 1727958.
DOI
2026 Vijayakumar, S., Khetan, R., & Sunna, A. (2026). The p40 fusion domain as a scaffold for producing functional inclusion bodies.. Applied microbiology and biotechnology, 110(1), 21 pages.
DOI Scopus1 WoS1
2026 Khetan, R., Donnellan, L., Collins, K., Kamath, S., Ariaee, A., Rajapaksha, W., . . . Joyce, P. (2026). The gut microbiota regulates the protein corona formation, biodistribution, and cellular uptake of lipid nanoparticles. Journal of Controlled Release, 395, 114995-1-114995-15.
DOI
2025 Khetan, R., Lokman, N. A., Eldi, P., Price, Z. K., Oehler, M. K., Brooks, D. A., . . . Albrecht, H. (2025). Protease-Activated Receptor F2R Is a Potential Target for New Diagnostic/Prognostic and Treatment Applications for Patients with Ovarian Cancer. International Journal of Molecular Sciences, 26(17), 8529.
DOI Scopus3 WoS4 Europe PMC4
2025 Muta, T., Khetan, R., Song, Y., & Garg, S. (2025). Optimising Cannabidiol Delivery: Improving Water Solubility and Permeability Through Phospholipid Complexation. International Journal of Molecular Sciences, 26(6), 28 pages.
DOI Scopus18 WoS17 Europe PMC7
2024 Khetan, R., Eldi, P., Lokman, N. A., Ricciardelli, C., Oehler, M. K., Blencowe, A., . . . Albrecht, H. (2024). Unveiling G-protein coupled receptors as potential targets for ovarian cancer nanomedicines: from RNA sequencing data analysis to in vitro validation.. J Ovarian Res, 17(1), 156.
DOI Scopus4 WoS4 Europe PMC3
2024 Abid, F., Virgo, E., Kennewell, T. L., Khetan, R., Haidari, H., Kopecki, Z., . . . Garg, S. (2024). The Acid-Buffered Engineered Gel Promotes In Vitro Cutaneous Healing and Fights Resistant Bacteria in Wounds. Pharmaceutics, 16(11), 15 pages.
DOI Scopus3 WoS3 Europe PMC2
2024 Rajapaksha, W., Khetan, R., Johnson, I. R. D., Blencowe, A., Garg, S., Albrecht, H., & Gillam, T. A. (2024). Future theranostic strategies: emerging ovarian cancer biomarkers to bridge the gap between diagnosis and treatment. Frontiers in Drug Delivery, 4(1339936), 19 pages.
DOI Scopus22 WoS13 Europe PMC7
2024 Saddam Hussain, M., Khetan, R., Albrecht, H., Krasowska, M., & Blencowe, A. (2024). Oligoelectrolyte-mediated, pH-triggered release of hydrophobic drugs from non-responsive micelles: Influence of oligo(2-vinyl pyridine)-loading on drug-loading, release and cytotoxicity. International Journal of Pharmaceutics, 661(124368), 15 pages.
DOI Scopus8 WoS7 Europe PMC5
2023 Saddam Hussain, M., Khetan, R., Clulow, A. J., Ganesan, R., MacMillan, A., Robinson, N., . . . Blencowe, A. (2023). Teaching an Old Dog New Tricks: A Global Approach to Enhancing the Cytotoxicity of Drug-Loaded, Non-responsive Micelles Using Oligoelectrolytes. ACS Applied Materials and Interfaces, 16(8), 9736-9748.
DOI Scopus6 WoS7 Europe PMC4
2023 Youssef, S. H., Kim, S., Khetan, R., Afinjuomo, F., Song, Y., & Garg, S. (2023). The development of 5-fluorouracil biodegradable implants: A comparative study of PCL/PLGA blends. Journal of Drug Delivery Science and Technology, 81(104300), 14 pages.
DOI Scopus25 WoS23
2022 Khetan, R., Dharmayanti, C., Gillam, T. A., Kübler, E., Klingler-Hoffmann, M., Ricciardelli, C., . . . Albrecht, H. (2022). Using GPCRs as Molecular Beacons to Target Ovarian Cancer with Nanomedicines. Cancers, 14(10), 1-32.
DOI Scopus15 WoS15 Europe PMC15
- Rajapaksha, W., Eldi, P., Gillam, T. A., Blencowe, A., Garg, S., Albrecht, H., & Khetan, R. (2026). Receptor Co‑targeting Strategies for Personalized Ovarian Cancer Therapy. International Journal of Nanomedicine, Volume 21, 1-16.
DOI

Year Citation
2025 Khetan, R., Eldi, P., Lokman, N., Ricciardelli, C., Oehler, M., Blencowe, A., . . . Albrecht, H. (2025). Leveraging GPCR overexpression for personalized nanomedicine: A novel approach in ovarian cancer therapy. In CANCER RESEARCH Vol. 85 (pp. 2 pages). IL, Chicago: AMER ASSOC CANCER RESEARCH.
DOI

Year Citation
2025 Khetan, R., Lokman, N. A., Eldi, P., Price, Z. K., Oehler, M. K., Brooks, D. A., . . . Albrecht, H. (2025). Protease-activated receptor F2R/PAR1 is a potential target for new diagnostic/prognostic and treatment applications for patients with ovarian cancer. Poster session presented at the meeting of CANCER RESEARCH. AMER ASSOC CANCER RESEARCH.
DOI

Courses I teach

  • BIOL 1050 Human Physiology 101 (2025)
  • CHEM 1007 Chemistry 101 (2025)
  • PHAR 2009 Drug Development 1 (2025)
  • PHAR 2010 Drug Discovery (2025)
  • CHEM 1006 Chemistry 100 (2024)
  • CHEM 1007 Chemistry 101 (2024)
  • PHAR 2009 Drug Development 1 (2024)

Connect With Me

External Profiles

Other Links